View Lumakras overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food: Swallow whole, do not chew/crush/split. For patients w/ difficulty swallowing, disperse tab in 120 mL of non-carbonated room temp water w/o crushing & stir until dispersed into small pieces. Drink immediately or w/in 2 hr. Rinse glass w/ additional 120 mL of water & drink. Do not chew tab pieces. For NG or PEG tube administration, follow tube's manufacturer's instructions w/ appropriate water flushes.
Special Precautions
Hepatotoxicity leading to drug-induced liver injury & hepatitis. Monitor LFT (ALT, AST & total bilirubin) prior to start, every 3 wk for the 1st 3 mth of treatment, then once a mth. Withhold, reduce dose or permanently discontinue treatment based on severity of adverse reaction. Immediately withhold treatment in patients w/ suspected ILD/pneumonitis & permanently discontinue if no other potential causes of ILD/pneumonitis are identified. Monitor patients for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (eg, dyspnea, cough, fever). Frequently monitor adverse reactions in patients w/ hepatic impairment. Pregnancy. Not to be used in lactation during treatment & for 1 wk after final dose. Ped patients.
Sign Out
